Head-to-head · Cost-Efficiency Index
Direct Meds vs Navio MD
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Direct Meds
Needle-averse shoppers who want a sublingual route on either molecule and will pay above the going rate for it, having accepted a three-month supply as the smallest unit sold.
Visit Direct MedsNavio MD
Shoppers who want compounded tirzepatide with a brand-name fallback path on the same platform, 48 states.
Visit Navio MDThe verdict
Navio MD takes it, leading the Cost-Efficiency Index 73 to 71. NavioMD is a 48-state telehealth platform selling compounded tirzepatide from $189/mo plus brand-name Ozempic, Zepbound, and Mounjaro at near-retail 'as low as' prices. Direct Meds still earns a C — Needle-averse shoppers who want a sublingual route on either molecule and will pay above the going rate for it, having accepted a three-month supply as the smallest unit sold.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Navio MD.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Direct Meds | Navio MD |
|---|---|---|
| Cost-Efficiency Index | 71/100 | 73/100 |
| Semaglutide / mo | $249/mo (sublingual, 90-day supply billed monthly) | $345/mo (brand Ozempic) |
| Tirzepatide / mo | $299/mo (sublingual, 90-day supply billed monthly) | $189/mo (starting dose, compounded) |
| Semaglutide / yr (modeled) | $2,988 | $4,140 |
| Tirzepatide / yr (modeled) | $3,588 | $2,268 |
| Coverage | Not disclosed | 48 states |
| Oral / sublingual | Yes | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #64 | #69 |
Direct Meds
71/100Where the value is
- Sublingual AND injection on BOTH molecules — four GLP-1 SKUs, the widest formulation range of any provider in this ranking
- Every price is published per SKU in a public shop, with no quiz, intake or email capture in front of it
- Each product page prints a per-day equivalent beside the monthly rate ($8.03/day at $249), which is unusually concrete for this category
The tradeoffs
- $249/mo sublingual is well above this ranking's ~$144 median, and the injection route is $297 — the cheapest thing here is dearer than most rows' headline price
- The only purchasable option on every product page is a 90-DAY SUPPLY billed monthly, so three months is the smallest unit sold — there is no month-to-month rate to compare against the rows beside it
Regulatory note: the FDA issued a warning letter to directmeds.com, Inc. dba DirectMeds in September 2025. We still list and link to Direct Meds; you should know the letter is on the public record before you decide.
Navio MD
73/100Where the value is
- LegitScript certified with board-certified providers claimed
- Both compounded and brand-name options on one platform
- 48-state coverage with the two exclusions (AL, MS) explicitly disclosed rather than hidden
The tradeoffs
- No compounded semaglutide offered — only brand-name Ozempic for that molecule, at a much higher price than compounded competitors
- All prices are 'as low as' floors; the exact dose tied to each starting price is not published
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.